Case Report

Acute ischemic stroke in COVID-19: a case report

Mamatha Tittamegalapalya Ramalingaiah*, Jeetendra Kumar Jogihalli Mood, Vinutha Bagalur Srinivas Murthy, Virender Singh

Department of Medicine, ESIC and PGIMSR, Bengaluru, Karnataka, India

Received: 13 July 2021
Accepted: 09 August 2021

*Correspondence: Dr. Mamatha Tittamegalapalya Ramalingaiah, E-mail: dr.mamatha87@gmail.com

ABSTRACT

Corona virus disease (COVID-19) is an infectious disease caused by SARS-CoV-2 virus. It predominantly affects respiratory system causing fever, cough, and breathlessness. But it can also affect central nervous system. Clinicians must adopt methodical approach in investigating a patient with neurological manifestation. Early detection and treatment is required for neurological disease of COVID-19 to reduce post COVID neurological sequel.

Keywords: Stroke, COVID-19, D-dimer, CRP

INTRODUCTION

According to world health organization, a case definition for a suspected COVID-19 patient is the presence of fever, cough and shortness of breath as typical clinical symptoms. Neurological manifestations like headache, dizziness, anosmia, taste impairment, cerebrovascular disease, encephalopathy, myositis have been reported in COVID-19 patients along with the classical symptoms of fever and respiratory involvement.1 A review by a panel of the World Stroke Organization reported that the risk of ischemic stroke during COVID-19 is around 5%.2 Patients with COVID-19 who had strokes were more likely to be older and have hypertension and higher levels of D-dimer.2 The median time from diagnosis to ischemic stroke in one small single-center study was 10 days.3 Similarly, among 50 patients with ischemic stroke admitted in Wuhan, China, there was more comorbidity, lower platelet counts, lower leukocyte counts, and higher levels of D-dimers, cardiac troponin I, NT probrain natriuretic peptide, and interleukin-6.4 Acute ischemic stroke (AIS) in brain is also emerging as an important neurovascular or neurological complication of COVID-19, associated with extreme immune responses leading to dysregulated coagulation system and generalized thrombo-embolic status and increased risk of acute ischemic stroke.5 It is currently unclear to what extent macrovascular complications contribute to the mortality and morbidity of COVID-19.6

CASE REPORT

65 years old female presented to us with chief complaint of right sided weakness of upper limb and lower limb since 4 days, which was sudden in onset, progressive in nature and attained maximum weakness on the first day. She also has history of loss of speech since 4 days. Patient was able to comprehend and was not able to speak. No history suggestive of cranial nerve involvement. No history suggestive of sensory involvement and cerebellar involvement. No history of bowel and bladder disturbances. Not a known case of hypertensive, diabetic disease or cardiac disease. No past history of transient ischemic attack or stroke. Patient also gives history of fever since 3 days, intermittent in nature, high grade associated with chills and rigors, subsided by taking medication. Dry cough since 2 days. No history of breathlessness and chest pain. On examination, patient...
was conscious, obeying to commands. Pulse rate was 110 beats per minute, blood pressure was 130/80mm Hg, respiratory rate was 28 breaths per minute. Temperature was 100°F. Oxygen saturation was 92 percent room air. CNS examination, patient had motor aphasia, hypotonia of right upper and lower limb. According to medical research council, power of right upper limb and lower limb was 2/5. Superficial reflexes were absent. Right plantar reflex was extensor. Left plantar reflex was flexor. Sensory system was normal. Cerebellar system and gait couldn’t asses. Skull and spine was normal. No signs of meningeal irritation. Other systemic examination was normal.

Arterial blood gas analysis was suggestive of type 1 respiratory failure. Blood investigations revealed haemoglobin 12.6 gm%, total count was 8060, neutrophils 79% lymphocytes 12%, NLR was 1.01, renal function test and liver function test was normal. Thyroid function test and lipid profile was normal. Glycosylated haemoglobin was 6.1%. Random blood sugar was 156 mg/dl. Serum LDH 127IU/l, d-dimer was 4.8, serum CRP was 27 mg/dl, serum ferritin was 39.7 µg/l, interleukin-6 was 0.18 pg/ml. ECG showed sinus tachycardia. Chest X-ray was suggestive of bilateral lower and mid zone infiltrates, predominantly peripheries (Figure 3). RT-PCR for SARS-CoV-2 was positive. CT brain plain revealed left inferofrontal and parieto-occipital infarct (Figure 1-2).

**DISCUSSION**

COVID-19 is a current worldwide pandemic with multiple complications. Studies has shown multiple neurological manifestations including cerebrovascular accidents in patients with severe infection. Arterial blood gas analysis was suggestive of type 1 respiratory failure. Blood investigations revealed haemoglobin 12.6 gm%, total count was 8060, neutrophils 79% lymphocytes 12%, NLR was 1.01, renal function test and liver function test was normal. Thyroid function test and lipid profile was normal. Glycosylated haemoglobin was 6.1%. Random blood sugar was 156 mg/dl. Serum LDH 127IU/l, d-dimer was 4.8, serum CRP was 27 mg/dl, serum ferritin was 39.7 µg/l, interleukin-6 was 0.18 pg/ml. ECG showed sinus tachycardia. Chest X-ray was suggestive of bilateral lower and mid zone infiltrates, predominantly peripheries (Figure 3). RT-PCR for SARS-CoV-2 was positive. CT brain plain revealed left inferofrontal and parieto-occipital infarct (Figure 1-2).

Patient was diagnosed with right sided hemiparesis with left sided ischemic stroke with COVID-19 pneumonia. Patient was started on oxygen 4 litres per minute, injection mannitol 100 ml three times daily, injection ceftriaxone 1 gm i.v. two times a day, injection dexamethasone 6 mg i.v. once a day, injection pantopon 40 mg i.v. twice a day, injection enoxaparin 40 mg subcutaneous twice a day, tab ecospirin 150 mg once a day, tab atorvastatin 40mg once a day. Power of right sided upper and lower limb gradually improved over period of 10 days, room air saturation improved to 95%. Patient was discharged with clinical improvement.

**DISCUSSION**

COVID-19 is a current worldwide pandemic with multiple complications. Studies has shown multiple neurological manifestations including cerebrovascular accidents in patients with severe infection. The current understanding on COVID-19 pathogenesis includes inflammation, endothelial dysfunction, and coagulopathy.
appear to play critical roles in COVID-19-associated cerebrovascular disease (CVD).8 Inflammatory processes of SARS-CoV-2 have fundamental roles in stroke in either the aetiology and pathophysiology of cerebral ischemia9, the presence of COVID-19 infection could be a factor in the genesis or worsening of stroke in addition to the potential risk of cardio-embolic stroke due to ACE-2 expression in the heart and subsequent cardiac dysfunction.10 Numerous studies have reported that recent respiratory infections are known to increase the short-term risk of ischemic stroke.11-16 Higher rates of strokes have been observed in patients with coronavirus disease 2019 (COVID-19) and large-vessel stroke has been reported as a presenting feature of COVID-19 in the young.17,18

Even though respiratory symptoms predominantly seen in COVID-19 patients, our patient presented with weakness of right upper limb and lower limb as chief complaint. Her CRP and d-dimer was elevated. This indicates that SARS-CoV-2 has increased affinity towards the ACE2 receptors which are expressed in endothelium and arterial smooth muscle cells in the brain, resulting in inflammatory process, endothelial dysfunction and prothrombotic state causing acute ischemic stroke in our patient. Final diagnosis in current investigation was acute ischemic stroke with COVID-19 pneumonia.

**CONCLUSION**

COVID-19 infection can be the independent risk factor for developing acute ischemic stroke due to its prothrombotic state. Those patients with neurological manifestations should be evaluated early and diagnostic work up and timely treatment should be done to prevent morbidity and mortality.

**Funding:** No funding sources  
**Conflict of interest:** None declared  
**Ethical approval:** Not required

**REFERENCES**

1. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;45(35):25-9.

2. Qureshi AI, Abd-Allah F, Alsennani F, Aytaç E, Borhani-Haghighi A, Ciccone A, et al. Management of acute ischemic stroke in patients with COVID-19 infection: Report of an international panel. Int J Stroke. 2020;2020;97:1-2.

3. Yaghi S, Ishida K, Torres J, Mac Groy B, Raz E, Humbert K, et al. SARS2-CoV-2 and stroke in a New York healthcare system. Stroke. 2020;50(6):2120-8.

4. Qin C, Zhou L, Hu Z, Yang S, Zhang S, Chen M, et al. Clinical characteristics and outcomes of COVID-19 patients with a history of stroke in Wuhan, China. Stroke. 2020;51(7):2219-23.

5. Wijeratne T, Sales C, Karimi L, Crewther SG. Acute ischemic stroke in COVID-19: a case-based systematic review. Front Neurol. 2020;11:1031.

6. Mohamed IZB, Balson L, Madathil S. Massive bilateral stroke in a COVID-19 patient. BMJ Case Rep. 2020;13:e236-54.

7. Srijavastava S, Srijavastava S, Kataria S, Melnic V, Adcock A, Sheikh Z. Neurological complications of COVID-19: a systematic review of literature. Front Neurol. 2020;10:212-6.

8. Nassir CMN, Hashim S, Wong KK, Abdul Halim S, Idris NS, Jayabalabn N, et al. COVID-19 infection and circulating microparticles-reviewing evidence as microthrombogenic risk factor for cerebral small vessel disease. Mol Neurobiol. 2021;26:1-28.

9. D’Anna L, Kwan J, Brown Z. Characteristics and clinical course of Covid-19 patients admitted with acute stroke. J Neurol. 2020;10:1007-12.

10. Madjid M, Safavi-Neiini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020;45:52-9.

11. Zurrù MC, Alonzo C, Brescacin L. Recent respiratory infection predicts atherothrombotic stroke: case-control study in a Buenos Aires healthcare system. Stroke. 2009;40:1986-90.

12. Cowan LT, Lutsey PL, Pankow JS. Inpatient and outpatient infection as a trigger of cardiovascular disease: the ARIC study. J Am Heart Assoc. 2018;7: e9683-9.

13. Grau AJ, Buggle F, Becher H. Recent bacterial and viral infection is a risk factor for cerebrovascular ischemia: clinical and biochemical studies. Neurol. 1998;50:196-203.

14. Bova IY, Bornstein NM, Korczyń AD. Acute infection as a risk factor for ischemic stroke. Stroke. 1996;27:2204-6.

15. Lindsberg PJ, Grau AJ. Inflammation and infections as risk factors for ischemic stroke. Stroke. 2003;34: 2518-32.

16. Becher H, Grau A, Steindorf K. Previous infection and other risk factors for acute cerebrovascular ischaemia: attributable risks and the characterisation of high-risk groups. J Epidemiol Biostat. 2000;5:277-83.

17. Escalard S, Maier B, Redjem H, Delvoye F, Hébert S, Smajda S, et al. Treatment of acute ischemic stroke due to large vessel occlusion with COVID-19: experience from Paris. Stroke. 2020;29:120-9.

18. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med. 2020;382:e60.

Cite this article as: Ramalingaiah MT, Mood JKJ, Murthy VBS, Singh V. Acute ischemic stroke in COVID-19: a case report. Int J Adv Med 2021;8:1430-2.